Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$202.04 USD

202.04
358,121

-2.37 (-1.16%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $201.98 -0.06 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up

Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.

Here's Why You Should Buy SmileDirectClub (SDC) Stock Now

Investors are likely to benefit from the SmileDirectClub (SDC) stock, backed by strategic alliances and targeted long-term growth.

Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised

Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 53.57% and 3.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra

Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

The Zacks Medical - Instruments industry is growing on rising demand for digital health. ALC, HOLX and PEN are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.

Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023

Penumbra (PEN) Gains on New Launches Amid Currency Headwind

Penumbra's (PEN) ability to improve net gross margins and EPS amid ongoing inflationary pressure and supply-chain headwinds buoy optimism.

Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover

If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).

Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes

Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.

Labcorp (LH) Announces Completion of the Fortrea Spin-off

Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.

Canopy Growth (CGC) Improves Liquidity With Another Selloff

Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

Investors are optimistic about Zimmer Biomet (ZBH) due to the continued procedure recovery and the strength of emerging markets.

Bruker (BRKR) Launches the SciY Platform of Software Solutions

Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.

Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe

Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.

Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems

Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.

BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology

The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.

OrthoPediatrics (KIDS) Unveils GIRO for Pediatric Orthopedics

The GIRO Growth Modulation System by OrthoPediatrics (KIDS) introduces a tether device designed specifically for pediatric patients.

Integra (IART) Completes Enrollment in the DuraSorb IDE Study

Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.

Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform

Bruker's (BRKR) new D6 PHASER platform is to be used for material analysis and advanced research.

Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now

HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.

Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind

Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.